麻豆传媒

Dr. L. Nelson Sanchez-Pinto is a pediatric critical care physician, biomedical informatics specialist, and clinical data scientist. He graduated from medical school at the Autonomous University of Barcelona in 2006, and then completed a Pediatrics residency program at Cincinnati Children's Hospital Medical Center in 2011, and a fellowship in Pediatric Critical Care Medicine at Children's Hospital Los Angeles (CHLA) in 2014. He obtained advanced fellowship training in informatics and data science research also at CHLA and completed a Masters of Biomedical Informatics program at Oregon Health & Science University in 2015. He then joined The University of Chicago as faculty where he obtained a KL2 Career Development Award. He later joined the faculty in the Departments of Pediatric and Preventive Medicine at Northwestern University Feinberg School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago in 2017.

Dr. Sanchez-Pinto is interested in discovering and evaluating data-driven phenotypes of critical illness by integrating clinical, physiologic, and multi-omics data. Dr. Sanchez-Pinto is particularly interested in developing data-driven approaches to study the complex interactions between the host response, the gut and lung microbiomes, and other clinical and genetic factors in patients with sepsis, acute respiratory distress syndrome (ARDS), and multiple organ dysfunction syndrome (MODS). His ultimate goal is to discover subgroups of patients who have similar phenotypes 鈥揳nd potentially similar response to targeted therapy鈥� in order to develop a personalized approach to critical illness.

Dr. Sanchez-Pinto is a pediatric critical care specialist and treats critically ill children with sepsis, ARDS, and MODS, as well as a host of other conditions. He has a special interest in advanced respiratory support, vasoplegia management, oxidative stress therapy, and metabolic support.

Raymond L. Woosley, MD, Ph.D., is a Flinn Scholar and professor of Biomedical Informatics and Medicine at the University of Arizona College of Medicine-Phoenix. He is also the founding president and chairman of the Board for AZCERT, Inc., a non-profit organization funded by the U.S. Food and Drug Administration to work with the College of Medicine to improve the safe use of medications.

Dr. Woosley received his medical degree from the University of Miami, FL; his doctorate in pharmacology from the University of Louisville, KY; and his bachelor's degree from Western Kentucky University. After an internship and residency in internal medicine, he completed a fellowship in clinical pharmacology at Vanderbilt University before joining the faculty as founding director of the Vanderbilt Cardiac Arrhythmia Center and rose to the rank of professor of Medicine and Pharmacology and associate director of the Vanderbilt Clinical Research Center.

In 1988, Dr. Woosley was appointed chairman of the Department of Pharmacology at Georgetown University Medical Center in Washington, D.C. He also served as associate dean for Clinical Research and director of the Institute for Cardiovascular Sciences. In 2001, Dr. Woosley joined the faculty at the University of Arizona as vice president of the Arizona Health Sciences Center and the dean of the College of Medicine. In 2005, he founded the Critical Path Institute (C-Path), an independent, non-profit organization created jointly by the U.S. Food and Drug Administration (FDA) and the University of Arizona to help implement the FDA鈥檚 Critical Path Initiative and accelerate the development of new drugs and diagnostics. In 2012, he founded the non-profit AZCERT, Inc.

Dr. Woosley鈥檚 research has been reported in more than 300 peer-reviewed publications and serves as the basis for eleven patents. For his contributions to medicine, Dr. Woosley has received numerous awards and honors from academic institutions, the Food and Drug Administration and professional societies.

Lajos Pusztai, MD, DPhil, is a medical oncologist who specializes in breast cancer. He is the co-director of the Genomics, Genetics, and Epigenetics Program at the Yale Cancer Center.
He says he enjoys the delicate work of helping patients overcome the fear and shock of a breast cancer diagnosis. “I ensure that they maximize their chance of cure through the best available treatments,” he says. “I also love the research component of my job, to push the boundaries of existing knowledge and developing new therapies.”
Dr. Pusztai says he gravitated to medical oncology at the beginning of his career because of an inspiring mentor, and that the best part of his job is seeing patients remain disease-free for years and continuing with their life.
He is chair of the Breast Cancer Research Committee of the South West Oncology Group (SWOG), a global cancer research community that designs and conducts publicly funded clinical trials. His research group has made important contributions to establish that estrogen receptor-positive and-negative breast cancers have fundamentally different molecular, clinical, and epidemiological characteristics.
He has been a pioneer in evaluating gene expression profiling as a diagnostic technology to predict chemotherapy and endocrine therapy sensitivity and has shown that different biological processes are involved in determining the prognosis and treatment response in different breast cancer subtypes. Dr. Pusztai is also the principal investigator of several clinical trials investigating new drugs, including immunotherapies for breast cancer.

, is senior associate dean for artificial intelligence, the founding director of the , professor of internal medicine, pathology and biomedical engineering, and director of the Clinical Image Analysis Lab at Wake Forest University School of Medicine.
Gurcan is an internationally recognized researcher and educator in the fields of medical image analysis, artificial intelligence and biomedical informatics.
He holds 10 patents for his interventions in medical artificial intelligence, which have led to the establishment of two startup companies.
Gurcan received his BSc and Ph.D. degrees in electrical and electronics engineering from Bilkent University, Turkey, and his MSc. degree in digital systems engineering from the University of Manchester Institute of Science and Technology, England.